Skip to content
HowShorted

Editas Medicine, Inc. short interest in 2022

In 2022, Editas Medicine, Inc.'s disclosed short interest ran from 16.56% of shares outstanding on 14 Jan 2022 to 31.48% on 30 Dec 2022, a change of +14.92 percentage points. The year's high was 31.48% on 30 Dec 2022 and its low 16.04% on 31 Jan 2022, averaging 22.54% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.48 days on 14 Oct 2022. Full history: Editas Medicine, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Editas Medicine, Inc. in 2022

2022 in figures

Start of year
16.56% (14 Jan 2022)
End of year
31.48% (30 Dec 2022)
Change
+14.92 pp
High
31.48% (30 Dec 2022)
Low
16.04% (31 Jan 2022)
Average
22.54%
Highest days to cover
14.48 (14 Oct 2022)
SEC filings marked
8

Every report in 2022

Editas Medicine, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202216.56%6.27
31 Jan 202216.04%4.49
15 Feb 202216.22%5.54
28 Feb 202216.71%6.8010-K filed, results (8-K)
15 Mar 202217.25%6.67
31 Mar 202217.94%6.71
14 Apr 202218.25%9.61
29 Apr 202218.38%7.49
13 May 202219.07%6.4010-Q filed, results (8-K)
31 May 202221.03%10.29
15 Jun 202221.30%11.16
30 Jun 202222.30%6.36
15 Jul 202223.86%9.37
29 Jul 202224.40%10.02
15 Aug 202223.64%9.3110-Q filed, results (8-K)
31 Aug 202224.26%10.83
15 Sep 202225.07%10.80
30 Sep 202226.41%10.44
14 Oct 202226.98%14.48
31 Oct 202226.86%13.38
15 Nov 202227.48%12.5710-Q filed, results (8-K)
30 Nov 202228.58%9.72
15 Dec 202230.79%9.98
30 Dec 202231.48%10.29

See also: Editas Medicine, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.